TLO 2.1 Respiratory Flashcards

1
Q

The Respiratory System Upper Airway

A
Upper Airway
• Nose
• Pharynx
• Adenoids & tonsils
• Epiglottis
• Larynx
• Trachea
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

The Respiratory System Lower Airway

A
Lower Airway
• Bronchi
• Bronchioles
• Alveolar ducts
• Alveoli
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

The Respiratory System Lungs

A
Lungs
• Right: 3 lobes
- upper
- mid
- lower
• Left: 2 lobes
- upper
- lower
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

The Respiratory System Chest Wall Structures

A

Chest Wall Structures
• Ribs
• Pleura
• Muscles (diaphragm)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Physiology of Respiration
Inspiration
Expiration

A

Ventilation – air moving from high
concentration to low

• Inspiration (active)
– Diaphragm
– Air moves down the pressure gradient

• Expiration (passive)
– Respiratory muscles relax returns to resting volume

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Physiology of Respiration Passageway Resistance

A

Respiratory Passageway Resistance – friction within the bronchioles
• Mucus, infection, tumors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Physiology of Respiration

Lung Compliance

A

Lung Compliance – the distensibility of the lungs

A liquid film, primarily composed of water, covers the alveolar walls. At any gas-liquid boundary, the molecules of liquid are more strongly attracted to each other than to gas molecules. This produces a state of tension called surface tension, that draws the liquid molecules even more closely together. The water content of the alveolar film compacts the alveoli and aids in the lungs recoil during expiration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Physiology of Respiration

Alveolar Surface Tension

A

Alveolar Surface Tension – draws liquid molecules
more closely together
• Surfactant – lipoprotein produced by alveolar cells
• Reduces surface tension, helping lungs expand

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Oxygen and Carbon Dioxide Transport

A

Diffusion – movement from high concentration
to low across alveoli-capillary membrane
• PaO2 = amt of oxygen dissolved in plasma
• PaCO2 = amt of carbonic acid dissolved in plasma
• SaO2 = amt of oxygen bound to Hgb
• 100% SaO2 = max amt Hgb can carry

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Controlling Respirations

A

Respiratory Centers = located in medulla oblongata and pons of the brain

Chemoreceptors = located in medulla and in the carotid and aortic bodies
• Respond to changes in arterial blood concentration of:
– Oxygen
– Carbon dioxide
– Hydrogen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Respiratory Alkalosis s/s

A
Seizures
Deep, rapid breathing
Hyperventilation
Tachycardia
Decrease or normal BP
Hypokalemia
Numbness/tingling of extremities
Lethargy/confusion
Light headedness
N/V
Causes: hyperventilation, anxiety, PE, fear
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Respiratory Acidosis s/s

A
hypoventilation= hypoxia
rapid, shallow respirations
Decrease BP
Skin/mucosa pale/cyanotic
HA
Hyperkalemia
Dysrhythmias= increase K+
Drowsiness
Dizziness
Disorientation
Muscle weakness
Hyperreflexia
Causes: resp depression, airway obstruction, overdose, increased cranial pressure, reduced alveolar cap diffusion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Respiratory Defense Mechanisms

A

Nasal Hair – filters our debris

Cilia – muscular, hair-like projections on cells that line the airway. Propels layer of mucus
Beats >1,000/min, moves mucous 0.5 to 1 cm/min
-Impaired by dehydration, smoking, infection, drugs

Mucus Layer – traps pathogens and other particles
Mucus and cilia are not in alveoli (bronchio tracks only)

Cough Reflex – high-pressure, high velocity airflow
Reflex Bronchoconstriction – prevents entry of irritants

Alveolar Macrophages – Phagocytize foreign particles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Subjective Respiratory Assessment

A

Review history - past diseases and
symptoms
• Medications – prescribed, OTC, herbals, PRNs, oxygen
• Surgery or treatments
• Family history
• Smoking history – often calculated in pack years or lifetime tobacco exposure.
• Pack year = twenty cigarettes smoked everyday for 1 year.
• Second-hand exposure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Subjective Respiratory Assessment

A
Assess health behaviors that affect respiratory status
• Nutrition
• Elimination
• Physical activity & exercise
• Sleep & rest
• Coping
• Roles & relationships
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Objective Respiratory Assessment

A

Physical exam of respiratory structures

Inspection= appearance, symmetry, resp rate and ease, signs of distress (cyanotic, use of accessory muscles or retractions, positioning, nasal flaring)

Palpation= tracheal position, sinuses comfortable to palpation, chest expansion, fremitus

Percussion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Objective Respiratory Assessment

A

Auscultation
• Apex to bases
• Compare side-to-side
• On skin – NOT over clothing

Normal breath sounds:
• Bronchial, bronchio-vesicular, vesicular

Abnormal breath sounds:
• Crackles, rhonchi, wheezes, friction rubs, positive voice sounds

Crackles: pneumonia, bronchitis, CHF

Wheezes: bronchitis, emphysema, asthma

Friction rubs: pleural inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Age Related Changes

Alterations in structure

A

Alterations in structure
• Decreased elastic recoil
• Decreased expiratory muscle strength
• Stiffening of chest wall = decreased compliance
• Increased AP diameter = barrel chest
• Spinal changes (kyphosis & lordosis) = decreased compliance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Age Related Changes

Reduced defense mechanisms

A
Reduced defense mechanisms
• Decreased immunity: cell-mediated, antibody production
• Decreased cilia function
• Decreased cough force
• Decreased alveolar function
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Acidosis vs Alkalosis

A

Acidosis (increased H+, decreased pH, increased PaCO2) = increased resp rate and volume

Alkalosis (decreased H+, increased pH, decreased PaCO2) = decreased resp rate and volume

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Respiratory Diagnostic Studies

Laboratory

A
Laboratory
Sputum
Gram stain
Culture & Sensitivity
Cytology 
Arterial Blood Gases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Respiratory Diagnostic Studies

Radiology

A
Radiology
CXR
CT Scan
MRI
PET
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Respiratory Diagnostic Studies

Bedside or OP Visit

A
Bedside or OP Visit
Peak Flow
Pulmonary Function
Skin tests
Pulse Oximetry
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Respiratory Diagnostic Studies

Procedural

A
Procedural
Thoracentesis
Endoscopy
Laryngoscopy
Bronchoscopy
Mediastinoscopy 
Biopsy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Classification of Respiratory Disease

Restrictive and Obstructive

A

Restrictive

  • Ventilation disorders
  • Decreased lung expansion
  • Decreased lung compliance/capacity

Obstructive

  • Gas exchange disorders
  • Increased compliance
  • Increased airway resistance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Restrictive Pulmonary Diseases

A

Pathophysiology: Decreased lung or thoracic compliance

Lung function: Decrease lung volume/capacities

Diseases
Tissue damage: Scarring or inflammation
-Limits lung expansion
-Impairs gas exchange
-“Stiff” lungs = lower lung volumes
-Pneumonia, TB, Fibrosis, Silicosis, Asbestosis, Tumors

Mechanical impairment: Limits chest wall and lung expansion
-Scoliosis, Obesity, Kyphosis, Lordosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Restrictive Pulmonary Diseases

Pneumonia

A

Acute inflammation of lung parenchyma

  • Significant morbidity & mortality in elderly
  • Infectious or noninfectious

Entry of organisms:

  • Aspiration – food, saliva, liquids, or emesis
  • Inhalation – microbes in air or droplets
  • Bloodstream – microbes move into the lungs

Lower pulmonary response:

  • Inflammation & alveoli edema
  • Exudate - mucous
  • Consolidation – lobar or bronchopneumonia
  • Resolution - macrophages
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Restrictive Pulmonary Diseases

What is pneumonia?

A

In pneumonia, the inflammatory response causes fluid to accumulate in the alveoli and edema to form as alveolar capillaries dilate and allow fluid to leak into interstitial tissues.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Restrictive Pulmonary Diseases

Types of Pneumonia

A

Community Acquired
Streptococcus pneumoniae – most common. Symptoms within first 2 days of hospitalization

Hospital Acquired
Onset > 48 hrs after admission

Aspiration
Chemical injury – acidic GI contents
Increased risk with enteral feedings

Opportunistic
Due to altered immune response. (HIV, malnourished, chemo, steroids)
Gradual onset

Secondary
Due to weakness form a concurrent illness. Think pneumocystis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Restrictive Pulmonary Diseases

Pneumonia – Clinical Manifestations

A

Onset of S/S usually sudden

  • Fever, SOB, cough, purulent sputum, pleuritic chest pain
  • Elderly – confusion often primary sx.
  • Other- atypical sx seen in older adults; HA, myalgias, fatigue, N/V/D, sore throat
  • Viral- “walking pneumonia”, less common, interstitial involvement, flu like sx, dry cough

Physical Exam
pulmonary congestion (bronchial breath sounds with crackles)
Increased fremitus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Restrictive Pulmonary Diseases
Primary Atypical Pneumonia
Mycoplasma pneumoniae

A

Mycoplasma pneumoniae - “walking pneumonia”

-College students and military recruits

-Highly contagious
–Pharyngitis or bronchitis
–Dry, hacking, nonproductive cough
–Systemic manifestations
Fever
Headache
Myalgias
Arthralgias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Viral Pneumonia

A

Mild disease

Greater incidence in:

  • Older adults
  • Chronic conditions
  • Cytomegalovirus (CMV) pneumonia is increasing in immunocompromised people.

Community epidemics

Influenza and adenovirus
-Dry cough, flu-like symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Restrictive Pulmonary Diseases

Pneumocystis Pneumonia

A

This type of pneumonia is caused by the yeast like fungus
Pneumocystis jiroveci. This fungus is common in the environment and does not cause illness in healthy people.

Pneumocystis jirovenci

  • Opportunistic or Secondary
  • AIDS, cancer, & other immunocompromised, chronic use of corticosteroids, organ/bone transplant

-Patchy involvement
Alveoli thicken, swell, and fill with fluid
May also have pneumatoceles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Restrictive Pulmonary Diseases

Manifestations of Pneumocystis Pneumonia

A
Tachypnea
SOB
Dry, nonproductive cough
Intercostal retractions
Cyanosis
Fever
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Restrictive Pulmonary Diseases

Aspiration Pneumonia

A

Risk Factors: Emergency surgery, depressed cough reflexes, dysphagia, enteric feedings, decreased LOC

Aspiration of gastric contents into lungs

Low p H of gastric contents causes inflammation

Pulmonary edema/respiratory failure can result

Complications: abscesses, bronchiectasis, gangrene of pulmonary tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Restrictive Pulmonary Diseases

Common symptoms of pneumonia

A
Sneezing, runny nose
Productive cough
Sore throat
Chest pain
Fatigue, muscle aches
Gray/bluish skin color
Sweats/chills
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Restrictive Pulmonary Diseases

Pneumonia - Complications Pleurisy

A

Inflammation of pleura

Painful – teach splinting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Restrictive Pulmonary Diseases

Pneumonia - Complications Pleural effusion

A

Fluid in pleural space

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Restrictive Pulmonary Diseases

Pneumonia - Complications Atelectasis

A

Collapsed, airless alveoli

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Restrictive Pulmonary Diseases

Pneumonia - Complications Bacteremia (sepsis)

A

Bacterial infection in blood

Bacteremia or sepsis is a leading cause of death for hospitalized elderly patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Restrictive Pulmonary Diseases
Pneumonia - Complication
Other rare complications

A

Other Rare complications include:
Lung abscess – localized area of necrosis & pus in lung
Empyema – pus in pleural cavity
Pericarditis – pericardium infected by spread
Meningitis – S. Pneumoniae
Endocarditis – infection spreads to endocardium & heart valves

42
Q

Restrictive Pulmonary Diseases

Pneumonia – Collaborative Care

A

Pneumococcal vaccine (s. pneumoniae)

Influenza vaccine

Antibiotics

  • Empiric (evaluate for multi-drug resistance)
  • Monitor response (fever, WBC, sputum, O2, CXR)
  • Typically, clinical improvement 3-5 days

Supportive care

  • Oxygen
  • Resp Tx: IS, CPT, flutter valves (vibration)
  • Nutritional support
43
Q

Restrictive Pulmonary Diseases
Pneumonia - Medications
Agent to “break up” mucus

A

Agent to “break up” mucus

Acetylcysteine
Potassium iodide
Guaifenesin

44
Q

Restrictive Pulmonary Diseases
Pneumonia - Medication
Broad-spectrum antibiotic

A

Broad-spectrum antibiotic

Macrolide
Penicillin
Second- or third-generation cephalosporin
Fluoroquinolone

45
Q

Restrictive Pulmonary Diseases
Pneumonia - Medication
Bronchodilators

A

Bronchodilators

Sympathomimetic drugs
Methylxanthines

46
Q

Restrictive Pulmonary Diseases

Pneumonia – Nursing Implications

A

Health Promotion and prevention

  • Risk reduction & good health habits
  • Prevent aspiration
  • Promote mobility
  • Pain control (promote C & DB, activity post-op, etc.)
  • Infection control & medical asepsis
  • Vaccination
47
Q

Restrictive Pulmonary Diseases

Prevent aspiration

A

Prevent aspiration

  • Decreased LOC (positioning, prevent pooling)
  • Oro or nasogastric tubes (HOB, residuals)
  • Swallowing difficulties (HOB, thickened liquids)
  • Ventilated patients
  • Can be “silent”
48
Q

Restrictive Pulmonary Diseases

Pneumonia – Nursing Implications

A

Acute interventions

  • Monitor physical assessment parameters (lung sounds, O2, VS, airway, hydration)
  • Provide treatments
  • Monitor response to treatments

Ambulatory & home care

  • Teach meds: complete all doses of antibiotics
  • Rest
  • Prolonged recovery
  • Vaccines
49
Q

Restrictive Pulmonary Diseases

Tuberculosis

A

Chronic, recurrent infectious disease usually affecting the lungs

Caused by Mycobacterium tuberculosis

Relatively slow-growing, acid-fast organism with a waxy outer capsule

Airborne transmission by droplet nuclei, Suspended in air for hours

50
Q

Restrictive Pulmonary Diseases

Tuberculosis – Clinical Manifestations

A

Early stage free of S/S

Active TB disease

  • Fatigue & malaise
  • Anorexia & weight loss
  • Low –grade fever
  • NIGHT SWEATS
  • Cough (can have purulent sputum and progress to hemoptysis in advanced stages)
  • System-specific signs with extrapulmonary
51
Q

Restrictive Pulmonary Diseases

Tuberculosis - Diagnosis

A

Mantoux skin tests – 0.1ml of PPD intradermal on forearm

  • Read by inspection and palpation at 48 – 72 hrs
  • Induration measured in mms (≥15mm + for all pts)
  • Positive result means exposure to TB has resulted in antibody formation
  • Interpreted considering size of induration + population risk factors
  • Two-step testing to eliminate false negatives

Blood test – (IGRAs), no false + for vaccinated

CXR

  • Upper lobe infiltrates or cavitary lesions
  • Lymph node involvement

Sputum for AFB (acid-fast bacilli)

C & S - Can take up to 8 wks due to slow growth

PCR – detects DNA from bacilli

52
Q

Restrictive Pulmonary Diseases

Tuberculosis – Drug Therapy Prophylaxis

A

Prophylaxis/Latent TB – treat with single drug

  • Isoniazid (INH) once daily for 6 – 9 months
  • Directly observed therapy (DOT) – twice weekly
  • Rifampin if resistant to isoniazid
53
Q

Restrictive Pulmonary Diseases

Tuberculosis – Drug Therapy Active TB

A

Active TB requires 2-4 drug regimen initially, up to 6 months

  • Isoniazid (INH)
  • Rifampin
  • Pyrazinamide
  • Ethambutol
  • Streptomycin
54
Q

Restrictive Pulmonary Diseases

Tuberculosis – Nursing Implications

A

Health Promotion

  • Screening: positive skin test = CXR
  • Mandatory reporting (health department)

Acute Intervention

  • Airborne isolation: neg pressure room, HEPA masks
  • Reduce spread – pt. education
  • Drug therapy
Ambulatory & Home Care
-DC to home 
Exposed contacts undergoing tx
-Compliance with drug regimen is critical
-Teach S/S of relapse
55
Q

Restrictive Pulmonary Diseases

Pulmonary fungal infections

A

Inhalation of fungal spores (exposure common)
Immune defenses usually prevent infection
High Risk = Immunocompromise
No person-to-person transmission
No isolation precautions
Can be deadly with disseminated disease
Antifungal meds specific to pathogen
Infections often have geographic distribution

56
Q

Restrictive Pulmonary Diseases

Types of Fungal Infections

A

Histoplasmosis – soil, birds & bats

  • Usually latent but can be chronic or fatal
  • Most common fungal infection in US

Aspergillosis (mold) – common in the environment

  • Rarely causes disease
  • Can cause thrombosis
  • Hemorrhaging possible if invades pulmonary blood vessels

Pneumocystis – common opportunistic pneumonia
Spreads via respiratory droplets
Asymptomatic infections can spread the organism

57
Q

Restrictive Pulmonary Diseases

Histoplasma capsulatum

A

Histoplasma capsulatum

Most infections develop into latent asymptomatic disease

Primary acute histoplasmosis
Mild, self-limiting influenza type illness

Chronic progressive disease
Older adults in lungs but can involve other organs

Disseminated histoplasmosis
Oftentimes fatal
Fever
Dyspnea
Cough
Weight Loss
Ulcerations of mouth and oropharynx
Muscle Wasting
Hepatomegaly
Splenomegaly
58
Q

Restrictive Pulmonary Diseases

Fungal infection treatments

A

Treatments
Oral itraconazole (Sporanox), a broad-spectrum antifungal agent, is commonly prescribed to treat histoplasmosis
Intravenous amphotericin B
surgery (lobectomy)

59
Q

Restrictive Pulmonary Diseases

Environmental (occupational) Lung Disease

A

Inhaled dust or chemicals

Effects depend on nature, duration, & intensity of exposure

  • Water solubility & particle size also a factor
  • Pneumoconiosis: inhaled dust (coal, asbestos) causes acute irritation leading to diffuse pulmonary fibrosis from recurrent tissue repair
  • Chemical pneumonitis: toxic chemical fumes inhaled, acute diffuse injury (pulmonary edema). Chronic exposure = bronchiolitis obliterans
  • Hypersensitivity pneumonitis: inhalation of antigens causing allergic response (farmers lung)
  • Lung cancer: often decades of delay in onset from exposure to development of cancer (asbestos = squamous cell carcinoma, adenocarcinoma, mesothelioma)
60
Q

Obstructive Respiratory Diseases

A

Obstructive airway disease increases resistance & affects gas exchange.

  • Anatomy affected: Airways
  • Breathing difficulty: Expiration
  • Pathophysiology: increased airway resistance, decreased diameter, turbulent air flow
  • Lung function: decreased airway flow rates, increased residual volume (trapped air)

Diseases: Asthma, COPD, Cystic Fibrosis, Bronchiectasis, Pulmonary Vascular Disease

61
Q

Obstructive Respiratory Diseases

Sleep Apnea

A

Intermittent absence of airflow RT upper airway obstruction or collapse; frequently associated with obesity

Risk factors:
Family member with sleep apnea, male gender, increasing age, obesity, large neck circumference

Manifestations:
Loud cyclic snoring, apneic periods, gasping, choking, restlessness or thrashing during sleep, excessive daytime sleepiness, personality and mental changes

62
Q

Obstructive Respiratory Diseases
Sleep Apnea
Complications, Diagnosis, Treatment

A

Complications:
Neurologic and behavior problems, HTN, HF, cardiac ischemia, dysrhythmias, pulmonary HTN

Diagnosis: 
Sleep study (home or sleep lab)

Treatment:
CPAP, BiPAP, wt loss, oral appliances, T & A surgery, neurostimulator (hypoglossal nerve stimulation)

63
Q

Obstructive Respiratory Diseases

Sleep Apnea – Nursing Care

A

Obstructive sleep apnea is often treated in the home

Education of patient and family

  • Equipment use
  • Strategies to decrease contributing factors
64
Q

Obstructive Respiratory Diseases

Asthma

A

Chronic inflammatory disorder of airways

Subacute

  • Inflammatory cells present
  • “quiet” or mild symptoms

Acute

  • Widespread airflow obstruction
  • Antigen-antibody response
  • Inflammatory mediators released
  • Bronchoconstriction, airway edema, impaired muco-ciliar clearance
  • May last 4 – 12 hours after trigger
65
Q

Obstructive Respiratory Diseases

Asthma Triggers

A
  • Allergens
  • Chemical agents in the workplace
  • Respiratory infections
  • Exercise
  • Emotional stress
  • Pharmacologic
  • -N S A I D s, beta-blockers, sulfites
66
Q

Obstructive Respiratory Diseases

Asthma - Manifestations

A

coughing
chest tightness
shortness of breath
wheezing

67
Q

Obstructive Respiratory Diseases

Status asthmaticus

A

Status asthmaticus
Severe, prolonged asthma
Does not respond to treatment

68
Q

Obstructive Respiratory Diseases

Asthma Medications

A

Long-term control

  • Anti-inflammatory agents
  • Long-acting bronchodilators
  • Leukotriene modifiers

Quick relief

  • Short-acting adrenergic stimulants
  • Anticholinergic drugs
  • Methylxanthines

Routes of administration
Metered-dose inhaler (MDI)
Dry powder inhaler (DPI)
Nebulizer

69
Q

Obstructive Respiratory Diseases

A

Bronchodilators
-Adrenergic stimulants, anticholinergic agents, and methylxanthines
In combination with anti-inflammatory

Anti-inflammatory agents

  • Corticosteroids
  • Cromolyn sodium and nedocromil

Leukotriene modifiers

  • Montelukast, zafirlukast, zileuton
  • Reduce need for short-acting bronchodilators
70
Q

Obstructive Respiratory Diseases

COPD

A

Pathophysiology

  • Chronic bronchitis and/or emphysema
  • Characterized by slow progressive obstruction of airways
  • -Resistance to airflow increases
  • -Expiration becomes slow or difficult
  • -Mismatch between alveolar ventilation and perfusion
  • -Impaired gas exchange
71
Q

Obstructive Respiratory Diseases

Chronic bronchitis

A

Chronic bronchitis : productive cough for 3 months in 2 successive years in pts in whom other causes of cough have been ruled out
damage to larger airways

72
Q

Obstructive Respiratory Diseases

Emphysema

A

Emphysema: abnormal permanent enlargement of airspaces distal to terminal bronchioles , with wall destruction and without obvious fibrosis
damage to alveoli

73
Q

Obstructive Respiratory Diseases
COPD Pathophysiology
Chronic Bronchitis

A

Chronic Bronchitis

  • Inhaled irritants cause chronic inflammation
  • Production of thick mucus
  • Productive cough lasting 3 or more months in 2 consecutive years
  • Narrowing of airways
  • Common recurrent infection
74
Q

Obstructive Respiratory Diseases
COPD Pathophysiology
Emphysema

A

Emphysema

  • Destruction of the walls of the alveoli
  • Enlargement of abnormal air spaces
  • Airway collapse
  • Loss of alveolar surface area for gas exchange
75
Q

Obstructive Respiratory Diseases

COPD - Manifestations

A
Classified according to severity, staged from 0 to 4
Stage 0: At risk
Stage 1: Mild 
Stage 2: Moderate
Stage 3: Severe
Stage 4: Very severe, life-threatening
  • Productive cough, often in mornings
  • Dyspnea with activity, exercise intolerance
  • Presence of a barrel-shaped chest
76
Q

Obstructive Respiratory Diseases

COPD stages

A

Stage 0: at risk. Lung function normal, but chronic cough and sputum production are present

Stage 1: Mild. Mild airflow limitation, usually with chronic cough and sputum production

Stage 2: Moderate. Worsening airflow limitation, usually with progressing manifestations including dyspnea on exertion

Stage 3: Severe. Further worsening of airflow limitation, increased shortness of breath, and repeated exacerbations impacting quality of life

Stage 4: Very severe. Severe airflow limitation with significantly impaired quality of life and potentially life-threatening exacerbations

77
Q

Obstructive Respiratory Diseases

COPD Physical examination

A

Physical examination:

  • Prolonged expiration auscultated in all lung fields
  • Wheezes or decreased breath sounds
  • Barrel-shaped chest & tripod position
  • Bluish-red discoloration of skin ( RT hypoxia & hypercapnia )
  • Anorexia & wt loss in advanced disease
  • ↑Hgb or anemia
78
Q

Obstructive Respiratory Diseases
COPD
ɑ-Antitrypsin deficiency

A

ɑ-Antitrypsin deficiency: serum protein produced in the liver that protects the lung tissue breakdown by proteolytic enzymes, causes bullous emphysema.
Early onset of COPD. Effects of AAT deficiency are exac greatly by smoking.
Autosomal recessive. One in 1700 to 3500 live births. Northern European descent most affected.
Treatable with Prolastin.

79
Q

Obstructive Respiratory Diseases

COPD Treatment

A
Smoking cessation
Avoidance of airway irritants and allergens
Pulmonary hygiene measures
Adequate nutrition & hydration
Pursed Lip Breathing 
Oxygen
Long-term oxygen therapy
Surgery
Lung transplant
Lung reduction surgery
80
Q

Obstructive Respiratory Diseases

COPD - Medications

A

PLEASE NOTE: Focus on learning these meds by the class. Some representatives of these med classes are on the course & program list. (hint!)
Medications for both asthma and COPD are chosen based on the classification of the degree of disease & step protocols

Think about the patho:
Meds that deal with excessive or thick mucus (expectorants)
Meds that decrease inflammatory response (corticosteroids)
Meds that dilate constricted airways (bronchodilators)

81
Q

Pathophysiology of Lung Cancer

A

Damage to genes

  • Genetic
  • Environmental
  • Behavioral

Majority of primary lung lesions are bronchogenic

  • Epithelium of bronchus or bronchiole
  • Differentiated by cell type

Spread via lymph system to other organs

82
Q

Types of Lung Cancer

Small-cell carcinoma

A

15% of all lung cancers
Central mass
Aggressive tumor

83
Q

Types of Lung Cancer

Adenocarcinoma

A

20-40% of all lung cancers
Peripheral mass
Early metastasis

84
Q

Types of Lung Cancer

Squamous cell

A

25-30% of all lung cancers

Central mass in large bronchi

85
Q

Types of Lung Cancer

Large cell carcinoma

A

10-15% of all lung cancers

Peripheral mass larger than adenocarcinoma

86
Q

Incidence and Risk Factors of Lung Cancer

A
Occupation (minerals, heavy metals)
Smoking/tobacco
Second hand smoke
Family history
Radon gas
Aging
Other illness such as COPD, TB
Pollution
Exposure to radiation
87
Q

Manifestations of Lung Cancer

A
Chronic cough
Hemoptysis
Wheezing, SOB
Dull, aching chest pain or pleuritic pain
Hoarseness and/or dysphagia
Fatigue, weakness
Bone pain
Clubbing
88
Q

Complications and Course of Lung Cancer

A

Superior vena cava syndrome
Partial or complete obstruction of superior vena cava

Paraneoplastic syndromes               
Syndrome of inappropriate ADH secretion (SIADH), 
hyponatremia, 
edema, 
Cushing Syndrome, 
hypercalcemia, 
venous thrombosis or pulmonary embolism.
89
Q

Paraneoplastic syndromes

A

Paraneoplastic syndromes are a set of symptoms that occur with cancer that are due to substances a tumor secretes or due to the body’s response to the tumor. They are most common with cancers of the lung, breast, ovary, and lymphomas, and may sometimes cause thefirstsymptoms of the disease. The symptoms vary widely depending on the particular substances responsible and may include symptoms of high calcium, symptoms of a low sodium level in the blood, symptoms related to a high cortisol level (Cushing’s syndrome), and others. Treatment usually focuses on treating the underlying cancer while managing the symptoms, such as high calcium.

90
Q

Diagnosis of Lung Cancer

A
Chest x-ray
Sputum specimen
Bronchoscopy
CT scan
Cytologic examination, biopsy
CBC, liver function, serum electrolytes
Tuberculin test
Pulmonary function tests, ABGs
91
Q

Treatment of Lung Cancer Medications

A

Medications
Combination chemotherapy treatment of choice for small-cell lung cancer
Bronchodilators

92
Q

Treatment of Lung Cancer Surgery

A

Surgery
Only real chance for cure in non-small cell lung cancers
Most tumors inoperable

93
Q

Treatment of Lung Cancer Radiation therapy

A
Radiation therapy
Used alone or in combination with surgery or chemotherapy
Either curative or palliative
“Debulks” tumors prior to surgery
Relieve manifestations, complications
94
Q

The Patient With a Laryngeal Tumor

A

Benign or malignant

  • Benign: Papilloma’s, Nodules, Polyps
  • Malignant: Squamous Cell Carcinoma most common

Chronic shouting, projecting, or vocalizing

Cigarette smoking and chronic irritation from industrial pollutants

95
Q

Pathophysiology and Manifestations of Laryngeal Tumors

A

Laryngeal cancer

-Most common malignancy is squamous-cell carcinoma

-Leukoplakia
White, patchy, and precancerous lesions

-Erythroplakia
Red, velvety patches thought to represent a later stage

Laryngeal cancer can develop in glottis, supraglotitis, and subglottis

96
Q

Pathophysiology and Manifestations of Laryngeal Tumors

A
Laryngeal cancer
-Well-differentiated, slow-growing
-Metastasis occurs late in illness
-Manifestations
Hoarseness
Change in voice quality

Cancer of supraglottis

  • Epiglottis, aryepiglottic folds, arytenoid muscles, cartilage, and false vocal cords
  • Invades locally, metastasizes early

Subglottic tumors

  • Below vocal cords
  • Often asymptomatic until it obstructs airway
97
Q

Risk Factors for Laryngeal Tumors

A
Tobacco use
ETOH
Poor nutrition
HPV infection
Exposure to asbestos
Race (more common in African American)
98
Q

Treatment of Laryngeal Tumors

A

Benign vocal cord polyps

  • Inhaled steroid spray
  • Some cases call for surgery

Radiation therapy

  • Treatment of choice
  • Preserves voice
  • Chemoradiotherapy

Chemotherapy

  • Treats distant metastasis
  • Palliation when tumor unresectable
  • Cisplatin and 5-fluorouracil
99
Q

Surgical Intervention for Laryngeal Tumors Goals

A

Goals

  • Remove the malignancy
  • Maintain airway patency
  • Achieve optimal cosmetic appearance
100
Q

Surgical Intervention for Laryngeal Tumors

A

Laser laryngoscopy
-carcinoma in situ, vocal cord polyps, & early vocal cord cancers

Laryngectomy

  • Partial laryngectomy
  • -Hemilaryngectomy
  • -Vertical partial laryngectomy
  • Total

Radical neck dissection

Modified neck dissection

101
Q

Post-Surgical Care for the Patient with a Laryngeal Tumor

The tracheoesophageal prosthesis (T E P)

A

The tracheoesophageal prosthesis (T E P)
diversion of air from the trachea through a one-way valve
esophagus and oropharynx
produces speech when stoma is occluded
prevents food from entering the trachea

102
Q

Post-Surgical Care for the Patient with a Laryngeal Tumor

Total laryngectomy

A

Total laryngectomy = permanent tracheostomy

-Speech rehabilitation